WTO to Continue Dialogue on Extending TRIPS Decision to Therapeutics and Diagnostics
By Guy José Bendaña-Guerrero & Asociados

At the October 30-31, 2023, meeting of the Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS), World Trade Organization (WTO) members continued their discussion on whether to extend the TRIPS Decision adopted at the 12th Ministerial Conference (MC12) to COVID-19 therapeutics and diagnostics.
Under paragraph 8 of the Ministerial Decision on the TRIPS Agreement, WTO members had agreed to make a decision on whether to extend this Decision to cover the production and supply of COVID-19 diagnostics and therapeutics, confirming members' right to override the exclusive effect of patents and provide greater scope to take direct action to diversify production of these products through clarifications of existing flexibilities and a targeted waiver over the next five years.
Members also reacted to the results of the United States International Trade Commission (USITC) report and a thematic session with external stakeholders dedicated to the issue.
While some members said that the USITC report confirmed that access to therapeutics and diagnostics went beyond the scope of intellectual property and that broader factors should be considered when making a decision, others argued that the report confirmed the insufficiency of voluntary licensing in responding to the pandemic. Others said they were still reviewing the content of the USITC report.
Many developing members urged the Council to arrive at a decision before the General Council meeting scheduled for December 2023. One member argued that sufficient evidence had now been provided to enable the Council to arrive at a decision. Other members reiterated their support for a consensus-based outcome.
